Skip to main content

Table 3 Summary of the study population used in this work.

From: Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients

Total number of patients 43
Male patients 76.7%
Response rate 48.8%
Median survival 9.43 months
Median time to progression 5.5 months
Median age 64 years
Range of age 39-74 years